Thursday, 6 June 2013

Healthtech Summit Announces Speakers and Teams up with Eucomed to Discuss the

Upcoming Changes in the European Regulatory Framework for Medical Devices

The Tech Tour and International Venture Club (IVC) announce that 20 promising Healthtech companies, with exciting new technologies, have been selected, from a shortlist of 200, to showcase their companies to an audience of leading international venture capitalists, corporate investors and executives at the fourth annual Healthtech Summit in London, June 25-26, 2013.

The theme of the Healthtech Summit this year is ‘Crossing the chasm from start-up to a sustainable high growth business’. This year’s Summit will be held at NYSE Euronext’s London office in the City of London. The Exchange has listed 69% of European Life Sciences IPOs over 2.5M€ since 2009, across all key markets of Western Europe. NYSE Euronext provides its community of 49 life sciences companies with access to the pool of specialized investors from the U.S., continental Europe and the UK.

Guy Lebeau, Company Group Chairman of Johnson & Johnson MD&D Europe and Chairman of Eucomed will give a presentation on the “Revision of the European Medical Devices Directives” and how it may impact the inflow of capital investments to Europe’s innovative SMEs. Hosted by Eucomed the discussion will focus on what kind of regulatory framework for medical devices is needed in Europe. Professor and author Nigel Nicholson, London Business School, will give the keynote speech at the Gala Dinner on the evening of June 25.

Panel discussions, designed by Co-Presidents Aris Constantinides, NBGI Ventures and Rudy Mareel, Ex-CEO of Synthon, will help participants evaluate the global investment landscape for growing companies, with a close focus on regulation and market access. In addition, speakers at the Summit will address themes high on the corporate and investor agenda such as financing sustainable high growth businesses and how to attract the right talent. Confirmed speakers include: David Cassak, Reed Elsevier; Ian Gilham, Biosurfit; Albert Ganyushin, NYSE Euronext; Daniel Mahoney, Polar Capital; Marie Meynadier, EOS Imaging; Alex Pasteur, Fidelity Biosciences; Andrea Ponti, JP Morgan; and Howard Rowe, Haymarket Financial.

The 20 companies showcasing at the summit were selected by a Committee led by Joey Mason of Delta Partners. The Selection Committee includes members from Albion Ventures, Atlante Ventures, BayCity Capital, Earlybird, Endeavour Vision, Fidelity Biosciences, Fountain Healthcare Partners, GIMV, HBM BioVentures, Imperial Innovations, Intesa SanPaolo, Inventages Venture Capital Investments, Lundbeckfond Ventures, Medica Venture Partners Israel, Neomed, NYSE Euronext, Omnes Capital, Salus Partners, Seroba Kernel, Sofinnova, Ysios Capital and the IVC Industry Group, led by Claus Andersson of Sunstone Capital.

The Excellence in Healthtech Award will be presented, by Brian Hashemi of Salus partners, during the opening ceremonies of the Gala Dinner. The award celebrates excellence in entrepreneurship and successful commercialization of innovative health technology in Europe making significant global impact in healthcare. The award is designed to highlight the successful development of a European company that has made significant achievements since their presentation at a prior Tech Tour Medtech Summit. Since its inception in 2008, the Healthtech Summits have profiled some of the most promising European Medtech companies.

About the Tech Tour - The Tech Tour was founded in Geneva in 1998 in response to the growing interest in emerging technology companies in various European regions. The Tech Tour is an independent, not-for-profit organization composed of key contributors to the high technology industry. The organization recognizes that continued prosperity in Europe lies in its ability to transform today's innovative projects into tomorrow's global technology

About the International Venture Club - The International Venture Club was founded in 2011 as the collaborative platform of leading venture investors promoting successful international investments. Its objectives are to 1) share better practices, 2) build co-investor trust and relations, 3) foster new funding and investment opportunities through joint actions and PR, 4) grow promising companies with corporate partners and co-investors and 5) keep a smart window and support to emerging innovative companies.